Home › Pulmonary Hypertension › Oklahoma › Oklahoma City
Pulmonary Hypertension clinical trials in Oklahoma City, OK
3 studies for Pulmonary Hypertension are looking for participants at sites in and around Oklahoma City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Recruiting
- University of Oklahoma, Oklahoma City
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RecruitingObservational study
- The University of Oklahoma Health Sciences Center, Oklahoma City
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Recruiting
- Integris Baptist Medical Center, Oklahoma City
About Pulmonary Hypertension
Pulmonary hypertension (PH) is high blood pressure in the arteries to your lungs. It makes your heart work harder, which can lead to heart failure.
More about Pulmonary Hypertension on MedlinePlus
Pulmonary Hypertension trials in other cities
- Philadelphia, PA10 studies
- Aurora, CO9 studies
- Phoenix, AZ9 studies
- Cincinnati, OH8 studies
- Indianapolis, IN8 studies
- New York City, NY8 studies
- Boston, MA8 studies
- Kansas City, KS8 studies
- Charleston, SC7 studies
- Rochester, MN7 studies
- Salt Lake City, UT7 studies
- Houston, TX7 studies
Other studies in Oklahoma City
- Non-Small Cell Lung Cancer28 studies
- Ovarian Cancer28 studies
- Endometrial Cancer25 studies
- Colorectal Cancer22 studies
- Prostate Cancer21 studies
- Lung Cancer19 studies
- Breast Cancer17 studies
- Metastatic Cancer16 studies
- Cancer (all types)14 studies
- Acute Myeloid Leukemia14 studies
- Head and Neck Squamous Cell Carcinoma13 studies
- Bladder Cancer11 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.